Literature DB >> 11343049

Glucocorticoid-remediable aldosteronism is associated with severe hypertension in early childhood.

R G Dluhy1, B Anderson, B Harlin, J Ingelfinger, R Lifton.   

Abstract

OBJECTIVES: To review the childhood course of glucocorticoid-remediable aldosteronism (GRA) in order to provide management guidelines for hypertension in children.
METHODS: Records for 20 children with GRA (aged 1 month to 18 years; 16 with hypertension) were retrospectively reviewed.
RESULTS: Of the 16 children with GRA who developed hypertension, 50% had moderate-severe hypertension (blood pressure [BP] >99th centile for age and sex); 32% had mild hypertension (BP >95th and <99th centile), and 18% had borderline normal BP (BP >90th and <95th centile). Eight of 16 children with hypertension who received directed monotherapy (glucocorticoid suppression or aldosterone receptor/sodium epithelial channel antagonists) maintained BP below the 90th centile. Three additional subjects receiving a combination of directed therapies or a combination of directed therapies and nifedipine were unable to achieve BP control. At GRA diagnosis, 5 of 8 children were normokalemic, and plasma renin activity was suppressed in 5 of 5 subjects.
CONCLUSIONS: Clinicians should have a high index of suspicion for GRA, especially in children with severe hypertension and a positive family history of early-onset hypertension and/or premature hemorrhagic stroke. Directed monotherapy is often successful in controlling BP in GRA.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11343049     DOI: 10.1067/mpd.2001.112648

Source DB:  PubMed          Journal:  J Pediatr        ISSN: 0022-3476            Impact factor:   4.406


  18 in total

1.  Non-glucocorticoid-remediable aldosteronism in an infant with low-renin hypertension.

Authors:  Maricarmen Malagon-Rogers
Journal:  Pediatr Nephrol       Date:  2003-11-25       Impact factor: 3.714

Review 2.  Does treatment-resistant hypertension exist in children? A review of the evidence.

Authors:  Ian Macumber; Joseph T Flynn
Journal:  Pediatr Nephrol       Date:  2019-05-30       Impact factor: 3.714

3.  Potassium regulation in the neonate.

Authors:  Melvin Bonilla-Félix
Journal:  Pediatr Nephrol       Date:  2017-04-04       Impact factor: 3.714

4.  A novel epithelial sodium channel beta-subunit mutation associated with hypertensive Liddle syndrome.

Authors:  Michael Freundlich; Michael Ludwig
Journal:  Pediatr Nephrol       Date:  2005-02-03       Impact factor: 3.714

Review 5.  Role of KCNJ5 in familial and sporadic primary aldosteronism.

Authors:  Paolo Mulatero; Silvia Monticone; William E Rainey; Franco Veglio; Tracy Ann Williams
Journal:  Nat Rev Endocrinol       Date:  2012-12-11       Impact factor: 43.330

6.  Genetic analyses of the chimeric CYP11B1/CYP11B2 gene in a Korean family with glucocorticoid-remediable aldosteronism.

Authors:  Ihn Suk Lee; Seul Young Kim; Hye Won Jang; Min Kyeong Kim; Ju Hee Lee; Yun Hyeong Lee; Young Suk Jo
Journal:  J Korean Med Sci       Date:  2010-08-14       Impact factor: 2.153

Review 7.  Genetic information in the diagnosis and treatment of hypertension.

Authors:  Maciej Tomaszewski; Lukas Zimmerli; Fadi J Charchar; Anna F Dominiczak
Journal:  Curr Hypertens Rep       Date:  2006-08       Impact factor: 5.369

8.  Pseudohyperaldosteronism, liquorice, and hypertension.

Authors:  Bruno Sontia; Jan Mooney; Lise Gaudet; Rhian M Touyz
Journal:  J Clin Hypertens (Greenwich)       Date:  2008-02       Impact factor: 3.738

9.  Liquorice health check, Oro-dental implications, and a case report.

Authors:  Louis Z G Touyz
Journal:  Case Rep Med       Date:  2009-07-08

Review 10.  Heritable forms of hypertension.

Authors:  V Matti Vehaskari
Journal:  Pediatr Nephrol       Date:  2007-07-24       Impact factor: 3.714

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.